IPSC
Century Therapeutics Inc

714
Mkt Cap
$416.78M
Volume
318.00
52W High
$2.71
52W Low
$0.3418
PE Ratio
-7.46
IPSC Fundamentals
Price
$2.32
Prev Close
$2.24
Open
$2.18
50D MA
$1.72
Beta
1.57
Avg. Volume
2.97M
EPS (Annual)
-$1.61
P/B
1.14
Rev/Employee
$43,926.67
$56.03
Loading...
Loading...
News
all
press releases
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen
TD Cowen assumed coverage on shares of Century Therapeutics in a report on Wednesday. They set a "buy" rating for the company...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Expands By 320.2%
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling...
MarketBeat·19d ago
News Placeholder
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Analysts
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat...
MarketBeat·25d ago
News Placeholder
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen cut Century Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday...
MarketBeat·29d ago
News Placeholder
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 148.0%
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 807,117 shares, a...
MarketBeat·1mo ago
News Placeholder
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·1mo ago
News Placeholder
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 32.1%
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling...
MarketBeat·1mo ago
News Placeholder
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Zacks·2mo ago
News Placeholder
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·2mo ago
News Placeholder
Century Therapeutics (NASDAQ:IPSC) Insider Buys 58,060 Shares
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Chad Cowan bought 58,060 shares of the business's stock in a transaction that occurred on Monday, December 22nd. The shares were...
MarketBeat·2mo ago
<
1
2
...
>

Latest IPSC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.